Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Joe McCracken On Early-stage Partnering In Asia: An Interview With PharmAsia News (Part 1 Of 2)

This article was originally published in PharmAsia News

Executive Summary

CHICAGO - Joe McCracken was a longtime head of business development for Genentech before he was brought into the Roche Group as Asia Regional Head for Roche Pharma Partnering, so he knows a few things about incorporating two organizations' visions of research projects when it comes to partnering.

You may also be interested in...



Roche's Joe McCracken On Early-stage Partnering In Asia: An Interview With PharmAsia News (Part 2 Of 2)

CHICAGO - Joe McCracken was a longtime head of business development for Genentech before he was brought into the Roche Group as Asia Regional Head for Roche Pharma Partnering, so he knows a few things about incorporating two organizations' visions of research projects when it comes to partnering.

Roche's Joe McCracken On Early-stage Partnering In Asia: An Interview With PharmAsia News (Part 2 Of 2)

CHICAGO - Joe McCracken was a longtime head of business development for Genentech before he was brought into the Roche Group as Asia Regional Head for Roche Pharma Partnering, so he knows a few things about incorporating two organizations' visions of research projects when it comes to partnering.

Roche Signs First In-licensing Deal In Korea With DigitalBiotech For Alzheimer's Disease Candidate

SEOUL - South Korea's DigitalBiotech signed a research collaboration and license option agreement with Roche covering DigitalBiotech's proprietary RAGE antagonist program targeting Alzheimer's disease

Related Content

UsernamePublicRestriction

Register

SC074864

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel